



## Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

Amita Patnaik<sup>1</sup> · Shirish Gadgeel<sup>2,5</sup> · Kyriakos P. Papadopoulos<sup>1</sup> · Drew W. Rasco<sup>1</sup> · Naomi B. Haas<sup>3</sup> · Hirak Der-Torossian<sup>4</sup> · Demiana Faltaos<sup>4,6</sup> · Diane Potvin<sup>4</sup> · Vanessa Tassell<sup>4</sup> · Manal Tawashi<sup>4,7</sup> · Richard Chao<sup>4</sup> · Peter J. O'Dwyer<sup>3</sup>

Published online: 5 April 2022

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

**Correction to: Targeted Oncology**  
<https://doi.org/10.1007/s11523-022-00875-0>

The article title, which reads

“Phase I Study of Glesatinib (MGCD256) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors”

should read

“Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors”

The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1007/s11523-022-00875-0>.

---

✉ Amita Patnaik  
amita.patnaik@startsa.com

<sup>1</sup> START, 4383 Medical Drive, Suite 4026, San Antonio, TX 78229, USA

<sup>2</sup> Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

<sup>3</sup> Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

<sup>4</sup> Mirati Therapeutics Inc., San Diego, CA, USA

<sup>5</sup> Present Address: Henry Ford Health System, Detroit, MI, USA

<sup>6</sup> Present Address: Olema Therapeutics, San Francisco, CA, USA

<sup>7</sup> Present Address: HUYABIO International, San Diego, CA, USA